Upon plan renewal starting January 1, 2026, BCBS Massachusetts no longer covers Wegovy, Saxenda and Zepbound for weight loss unless an employer with more than 100 employees chose to keep the benefit. Groups under 100 and direct-pay members lost it when their plan renewed; GLP-1s for type 2 diabetes remain covered.
By Dr. SkinnyVIP · Published October 19, 2026 · Quotes link to the original policy or report
“If your company has more than 100 employees, your employer will have the option to continue coverage. If they choose not to, upon plan renewal starting January 1, 2026, Wegovy, Saxenda, and Zepbound will no longer be covered, even if you're currently using them.”
“If your company has fewer than 100 employees or you're a direct-pay member, you're not eligible to continue coverage. If you're taking a GLP-1 for weight loss, the change will go into effect when your plan renews in 2026. After that date, your authorization for the medication will expire and you'll no longer have coverage.”
Because the change applies at renewal, some members lost coverage in January and others later in 2026, which is why the question keeps coming up months after the announcement.
The insurer's page says it remains committed to covering GLP-1 medications for type 2 diabetes. Medicare Advantage and stand-alone Part D members were never covered for weight-loss GLP-1s under this plan, as those follow CMS rules; Part D members may instead qualify for the Medicare GLP-1 Bridge.
If you work for a company with more than 100 employees: ask HR directly whether the company elected to keep GLP-1 weight-loss coverage. It is a choice they made, and they can tell you in one sentence.
1. Ask your plan one question in writing. “Is there a continuation-of-therapy or medical-necessity exception for members already on a GLP-1, and what documentation does it need?” Many policies keep an exception for diabetes, cardiovascular risk reduction, sleep apnea or liver disease; a letter from your prescriber may qualify you.
2. Check the two public cash-pay routes for the brand-name drug. LillyDirect sells Zepbound to self-pay patients at published prices by dose ($299 to $699 a month for vials as of October 2026, per our Real-Price Index). If you are on Medicare Part D, the Medicare GLP-1 Bridge offers Wegovy or Zepbound for a $50 copay through December 2027 if you meet its criteria (details).
3. If neither fits, know the compounded option's real number. SkinnyVIP's clinician-prescribed compounded tirzepatide is $695 for a 3-month plan (about $232 a month) or $350 for a single month, the same price at every dose, with no membership, no subscription and no automatic renewal; you pay once per plan and nothing bills again unless you ask. If a licensed clinician does not prescribe, the medication cost is refunded in full. Compounded medications are not FDA-approved products; read how it works and what that means before deciding.
For type 2 diabetes, yes. For weight loss, only if you are in an employer group of more than 100 employees that chose to keep the benefit; otherwise coverage ended when your plan renewed in 2026, per the insurer's page.
The insurer's page says groups under 100 and direct-pay members were not eligible to continue coverage and that authorizations expire at renewal. Your remaining routes are the brand-name cash price, the Medicare Bridge if you are on Part D, or compounded tirzepatide.
No. The page states coverage ends at renewal 'even if you're currently using them' unless your large-group employer kept it.
$695 for a 3-month plan (about $232 a month) or $350 for one month, any dose, no membership, nothing renews. Compounded medications are not FDA-approved products; a licensed clinician decides whether to prescribe.
Ask your plan about exceptions, check the brand-name cash routes, then compare. SkinnyVIP: $695 for 3 months (about $232/month) or $350 for one, any dose, nothing renews.
Start your consultationCompounded tirzepatide is prepared by licensed compounding pharmacies under physician supervision. Compounded medications are not FDA-approved products, and FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Compounded tirzepatide is separate from FDA-approved Mounjaro® and Zepbound®. A licensed clinician reviews every request; prescription is not guaranteed. Individual results vary. Not affiliated with Novo Nordisk (Ozempic®/Wegovy®) or Eli Lilly (Mounjaro®/Zepbound®). This page is general information about published coverage policies, not insurance, legal or medical advice; confirm details with your plan.